Abattis Names Brazos Minshew Chief Science Officer
May 6, 2015 (Source: Abattis Bioceuticals Corp.) — Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CSE: ATT), specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets — some of which will contain cannabinoid compounds, today announced that Brazos Minshew, former Chief Science Officer of TriVita, Inc., former Chief Executive Officer of Therapy Alternatives and Director of Marketing for Tiena Health, will assume the role of Chief Science Officer (“CSO”) of Abattis Bioceuticals Corp. effective April 20, 2015.
Brazos has been consulting for the Company since July 2014 and the Company is pleased to see him assume a larger role. Brazos commented, “By strengthening our scientific base, we look to obtain a leadership position for Abattis in deployment of innovative and breakthrough nutrition products that will improve human health for many years to come.”
About Abattis Bioceuticals Corp.
Abattis is For more information, visit the Company’s website at: www.abattis.com.
Abattis is a specialty biotechnology company that aggregates, incubates, integrates and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets — some of which will contain cannabinoid compounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at:www.abattis.com.
ON BEHALF OF THE BOARD
William Fleming, Director & CEO
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
Raj Shah has been a member of the InvestorIntel.com team for the last nearly 9 years. Recruited from Merrill Lynch, he has over 13 years’ ... <Read more about Raj Shah>